|Tested species reactivity||Virus|
|Published species reactivity||Virus, Human, Mouse|
|Host / Isotype||Mouse / IgG2a, kappa|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||0.2-0.4 µg/mL|
|Immunohistochemistry (IHC)||2-4 µg/ml|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||0.5-1.0 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13640 targets Adenovirus Type 5 E1A in IF, IHC, IP, and WB applications and shows reactivity with Virus samples.
The MA5-13640 immunogen is adenovirus.
The early region (E1A) of the adenovirus genome plays a central role in cellular transformation and regulation of gene expression. The E1A region encodes a series of related proteins (35-46kDa) with multifuctional capabilities and form a specific complex with the retinoblastoma tumor suppressor gene product (Rb protein). The E1A and E1B regions together comprise the transforming region of adenovirus. While expression of E1A alone is sufficient to immortalize primary cells, complete transformation requires the additional expression of the E1B region. Several conserved regions of E1A are similar to portions of other viral oncoproteins like the HPV-16 and HPV-18 E7 and SV40 large T antigen.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
MA5-13640 was used in western blot to study the mechanism by which a combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma
|Ulasov IV,Sonabend AM,Nandi S,Khramtsov A,Han Y,Lesniak MS||British journal of cancer (100:1154)||2009|
Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell.
MA5-13640 was used in western blot to develop urothelium-specific adenovirus for bladder cancer treatment
|He XD,Wang ZP,Wei HY,Zhou Q,Wang DG,Tian JQ,Fu SJ,Rodriguez R||Urologia internationalis (82:209)||2009|
Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.
MA5-13640 was used in western blot to study the use of double mutant oncolytic adenovectors in anti-glioma gene therapy
|Ulasov IV,Tyler MA,Rivera AA,Nettlebeck DM,Douglas JT,Lesniak MS||Journal of medical virology (80:1595)||2008|
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.
MA5-13640 was used in western blot to study the oncogenic function of a leukemia-associated cytoplasmic nucleophosmin mutant
|Cheng K,Grisendi S,Clohessy JG,Majid S,Bernardi R,Sportoletti P,Pandolfi PP||Oncogene (26:7391)||2007|
Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
MA5-13640 was used in western blot to study the antitumor selectivity and therapeutic potential of a dual promoter-controlled oncolytic adenovirus in preclinical models
|Li Y,Idamakanti N,Arroyo T,Thorne S,Reid T,Nichols S,VanRoey M,Colbern G,Nguyen N,Tam O,Working P,Yu DC||Clinical cancer research : an official journal of the American Association for Cancer Research (11:8845)||2005|
Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.
MA5-13640 was used in immunocytochemistry and western blot to study the mechanism by which oncolytic adenoviral vectors using the survivin promoter induce glioma oncolysis
|Ulasov IV,Tyler MA,Zhu ZB,Han Y,He TC,Lesniak MS||International journal of oncology (34:729)||2009|
Cancer therapy utilizing an adenoviral vector expressing only E1A.
MA5-13640 was used in immunocytochemistry and western blot to develop an adenoviral vector expressing only E1A for cancer therapy
|Hubberstey AV,Pavliv M,Parks RJ||Cancer gene therapy (9:321)||2002|
Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.
MA5-13640 was used in immunohistochemistry to investigate the anti-tumor efficacy of a recombinant adenovirus H101 in combination with chemotherapy in patients with late stage cancers
|Lu W,Zheng S,Li XF,Huang JJ,Zheng X,Li Z||World journal of gastroenterology (10:3634)||2004|